Reirradiation in locally recurrent rectal cancer is one of the most complex areas in gastrointestinal radiation oncology.
Many patients with locally recurrent rectal cancer have already received pelvic radiotherapy during treatment for their primary disease. Historically, this limited the use of further radiotherapy because of concerns about serious toxicity. However, advances in conformal radiotherapy, image guidance, dose planning, and precision delivery have renewed interest in reirradiation as part of multimodal care.
New ESTRO recommendations, endorsed by ASTRO, provide practical guidance for the use, planning, and delivery of reirradiation in locally recurrent rectal cancer.
Why This Guidance Matters
Locally recurrent rectal cancer remains a difficult clinical problem.
Radiotherapy may be used in the neoadjuvant setting to improve the chance of radical resection, as definitive treatment for local control and symptom control, or as palliative treatment for symptom relief.
Many patients with locally recurrent rectal cancer have previously received radiotherapy, making treatment decisions more challenging.
The guideline notes that advances in radiotherapy technology now allow more precise and conformal treatment, supporting renewed use of reirradiation in selected patients.
At the same time, the evidence base remains limited, and approaches vary widely between institutions. This creates a need for practical recommendations that can improve consistency, safety, and treatment quality.
How the Recommendations Were Developed
The recommendations were developed by the ESTRO Guidelines Committee through the Lower Gastrointestinal Cancer Sub-Committee. A multidisciplinary writing committee performed a systematic literature review following PRISMA guidance.
The group addressed 14 key questions related to indications, planning, and delivery of reirradiation in locally recurrent rectal cancer. Recommendations were based on available evidence or expert consensus and graded using the ASTRO grading system.
The authors emphasize that most evidence remains low quality, with many recommendations based on expert opinion. This highlights the need for prospective studies, registry data, and standardized reporting.
Patient Selection and Multidisciplinary Review
A central message of the guideline is that reirradiation should be individualized.
The benefit-risk ratio depends on the patient’s disease status, recurrence anatomy, prior radiotherapy dose, time interval since previous treatment, prior surgery, previous systemic therapy, performance status, symptoms, life expectancy, and patient goals.
The guideline strongly recommends that all patients be discussed in a specialist multidisciplinary team with experience in rectal reirradiation.
This team should preferably include radiation oncologists, medical oncologists, surgeons, radiologists, and, when available, palliative care physicians.
The guideline also stresses the importance of discussing benefits, risks, uncertainties, treatment aims, and possible quality-of-life impact with patients.
Treatment Intent
The recommendations distinguish between three main treatment settings.
Neoadjuvant reirradiation may be considered before radical surgery to improve the chance of R0 resection.
Definitive reirradiation may be considered for patients who are not suitable for surgery or have unresectable disease, with the goal of prolonged local control and symptom control.
Palliative reirradiation may be used for symptom relief in patients with limited life expectancy, poor performance status, or symptomatic pelvic disease.
This distinction is important because dose, fractionation, organ-at-risk priorities, and acceptable risk may differ depending on treatment intent.
Dose and Fractionation
For neoadjuvant reirradiation, the guideline supports several commonly used dose schedules.
Recommended options include 30 Gy in 1.8–2 Gy daily fractions, 30–39 Gy in 1.5 Gy twice-daily fractions, or 40.8 Gy in 1.2 Gy twice-daily fractions. An intraoperative radiotherapy boost may be considered when clinically and logistically appropriate.
For definitive reirradiation, schedules similar to the neoadjuvant setting may be used when the goal is prolonged local control. For palliative reirradiation in symptomatic patients with poor performance status or expected survival under 6 months, shorter regimens such as 1 × 8 Gy or 5 × 4 Gy are described as reasonable patient-friendly options.
Advanced Radiotherapy Techniques
The guideline discusses several advanced approaches, including SBRT, proton therapy, and carbon ion therapy. SBRT may be considered for carefully selected patients with 1–3 small discrete lesions, without invasion of the gastrointestinal tract or bladder, and in centers with appropriate experience.
Proton therapy may be considered for neoadjuvant or definitive reirradiation in experienced centers where available. Carbon ion therapy may also be considered in selected centers with expertise and access.
However, the guideline emphasizes that there are limited data to guide selection of these techniques, and there is no definitive evidence that one external beam modality is superior for all patients.
Treatment Planning
Planning reirradiation for locally recurrent rectal cancer is technically challenging.
The guideline recommends obtaining previous radiotherapy details whenever possible, ideally including prior 3D imaging, structures, and dose distributions. If full 3D data are not available, clinicians should collect as much information as possible to reconstruct previous field borders and estimate prior dose exposure.
For neoadjuvant or definitive reirradiation, treatment should be delivered using IMRT, VMAT, or a comparable inverse-planned technique. The guideline also recommends using established contouring guidance, particularly the PelvEx II delineation guideline, especially in the neoadjuvant setting.
Cumulative Dose and Organs at Risk
One of the most difficult aspects of rectal cancer reirradiation is evaluating cumulative dose to organs at risk.
The guideline states that reirradiation planning should account for previous radiotherapy dose, and cumulative equieffective dose to normal tissue should be evaluated. There is no single universally safe organ-at-risk threshold.
Based on available series and expert opinion, cumulative EQD2Gyα/β=3Gy below 90 Gy may often be deliverable to the planned target volume with acceptable levels of severe toxicity, but the authors caution that this is not a universal safe threshold.
Dose evaluation must be interpreted in the context of organ-specific dose-volume parameters, overlap volume, prior toxicity, clinical intent, and patient goals.
Image Guidance and Adaptive Radiotherapy
The guideline supports daily volumetric imaging for SBRT and recommends that it should be strongly considered for neoadjuvant and definitive reirradiation when there is concern about specific organs at risk.
Cone-beam CT with online correction is commonly used.
MR-guided platforms may improve visualization in cases complicated by fibrosis or distorted anatomy. Daily adaptive radiotherapy may help spare mobile bowel close to recurrent disease, particularly when high-dose treatment is delivered near sensitive organs.
Concurrent Radiosensitizers
The guideline recommends concurrent oral or intravenous fluoropyrimidines with reirradiation in the neoadjuvant or definitive setting, when patient factors allow.
Capecitabine or 5-fluorouracil are the most commonly used radiosensitizers in published series. Other systemic combinations remain investigational.
Regional hyperthermia may be considered in experienced centers, ideally within a clinical trial, but evidence is not strong enough to define which patients benefit most.
Clinical Interpretation
These recommendations are important because they provide a practical framework for a treatment area that has often lacked standardization. Reirradiation may help improve R0 resection rates, enhance local control, and relieve symptoms in selected patients with locally recurrent rectal cancer.
However, the guideline does not present reirradiation as a simple option for every patient. Safe use requires specialist multidisciplinary review, careful patient selection, prior dose assessment, cumulative dose evaluation, precise planning, image guidance, and experienced radiotherapy teams.
The recommendations also make clear that patient goals and quality of life should remain central to decision-making.
Evidence Gaps
The guideline repeatedly notes that high-level evidence is limited.
Most available data come from retrospective studies, small prospective trials, and expert consensus. The authors strongly encourage participation in national and international databases and trials, including ReCare, UK SABR audit, PelvEx II, ReRad, RETRY, PRIOR, and ReCOG collaborations.
Future studies are needed to define optimal patient selection, dose and fractionation, organ-at-risk constraints, use of advanced modalities, and long-term toxicity outcomes.
Clinical Takeaway
ESTRO recommendations, endorsed by ASTRO, provide practical guidance for reirradiation in locally recurrent rectal cancer.
The guideline supports reirradiation in selected patients with neoadjuvant, definitive, or palliative intent.
Key principles include specialist multidisciplinary review, patient-centered discussion of risks and goals, assessment of prior radiotherapy and cumulative dose, use of advanced planning and image guidance, and delivery by experienced teams.
In the absence of high-level evidence, these recommendations offer an important expert consensus framework to support safer and more consistent rectal cancer reirradiation in routine clinical practice.
Read full article here.
